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Abstract
Background: Tendon disorders (tendinopathies) pose serious biomedical and socioeconomic problems. Despite 
diverse treatment approaches, the best treatment strategy remains unclear. Surgery remains the last resort because of 
the associated morbidity and inconsistent outcomes. We hypothesized that, similar to fibroblasts in various organs, 
tendon fibroblasts (tenocytes) might be responsive to stimulation with interleukins (ILs), particularly IL-4 and IL-13. 
These two cytokines share sequence homology, receptor chains and functional effects, including stimulation of 
fibrogenesis. It is unknown whether tenocytes are responsive to stimulation with IL-4 or IL-13. If true, local use of these 
cytokines might be used to facilitate tendon repair in patients with tendinopathies or used for tendon tissue-
engineering approaches to facilitate tenocyte growth on scaffolds in culture.
Results: Tendon tissues that would normally be discarded were obtained during reconstructive surgery procedures 
performed for clinical indications. Primary tenocytes were derived from Achilles, posterior tibial, flexor digitorum longus 
and flexor hallucis longus tendon tissue samples. Reverse transcriptase quantitative PCR (RT-qPCR) experiments 
revealed that mRNAs for the receptor (R) chains IL-4Rα, IL-13Rα1 and IL-13Rα2, but not the common γ-chain were 
present in all tested tendon tissues and in cultured tenocytes. Levels of IL-13R chain mRNAs were significantly higher 
than those of IL-4R mRNA. The cultures responded, in a dose-dependent fashion, to stimulation with recombinant 
human IL-4 or IL-13, by increasing proliferation rates 1.5 to 2.0-fold. The mRNA levels of 84 genes related to cell cycle 
regulation were measured by RT-qPCR after 6 h and 24 h of activation. The expression levels of several genes, notably 
CDK6 and CDKN2B changed more than twofold. In contrast to their effects on proliferation, stimulation with IL-4 or IL-
13 had little if any effect on the levels of collagen mRNA or protein in cultured primary tenocytes. The mRNA levels of 
84 other genes related to extracellular matrix and cell adhesion were also measured by RT-qPCR; expression of only five 
genes was consistently changed.
Conclusions: Stimulation with IL-4 or IL-13 could be used to facilitate tendon repair in vivo or to aid in tendon tissue 
engineering, through stimulation of tenocyte proliferation.
Background
Tendon disorders (tendinopathies) are common, and are
responsible for much morbidity in sportspersons [1,2],
military personnel [3,4] and in the workplace [5,6]. Tendi-
nopathies are associated with trauma, age, male gender,
chronic renal or endocrine disease, diabetes [7,8], rheu-
matoid arthritis [9,10], obesity, steroid therapy, and ther-
apy with fluoroquinolone antibiotics [10,11]. African
American or Latino ethnicity increases the risk for major
tendon ruptures [3,4]. Tendinopathies of the Achilles ten-
don (AT) and posterior tibial tendon (PTT) are most
common [12]. The mechanisms of tendinopathies are
complex, and involve mechanical stress, degenerative
changes in the tendon tissue and disorganized healing,
along with a contribution from inflammatory processes,
although it is unclear [7,13]. The molecular mechanisms
of tendinopathies have not been investigated in detail.
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The treatment approaches to tendinopathies are
diverse, but the optimum treatment remains undeter-
mined, with surgery being the last resort, because of the
associated morbidity and inconsistent outcomes [14]. We
propose that novel approaches to treating tendinopathies,
including postoperative care, should facilitate local teno-
cyte proliferation and thus strengthen the healing tendon
metabolically and mechanically. Tenocytes are collagen-
producing mesenchymal cells that make up the majority
of cells in a healthy tendon, but unlike fibroblasts in other
organs, they express the proteins tenomodulin and scler-
axis [15]. Fibroblasts from various organs consistently
respond to stimulation with numerous cytokines, by
adjusting the rates of proliferation and collagen produc-
tion [16,17]. Therefore, it is plausible that local adminis-
tration of cytokines to healing tendons may be beneficial
in facilitating tenocyte proliferation and thus the overall
tendon repair. Additionally, fibroproliferative cytokines
may prove useful in tendon tissue-engineering
approaches, to facilitate growth of primary human
(including autologous) tenocytes on artificial scaffolds,
for subsequent use as implants during reconstructive ten-
don surgeries.
Interleukin (IL)-4 and IL-13 are prototypic immuno-
modulatory T-helper (Th)2 cytokines known to have pro-
fibrotic effects [16-18]. These two cytokines share
sequence homology and cell surface receptor chains,
including IL-4Rα, IL-13Rα1, IL-13Rα2 and the common
gamma chain (γc). They also share numerous immuno-
modulatory effects and, relevant to our study, effects on
proliferation and gene expression in fibroblasts of diverse
tissue origin [16-18]. We hypothesized that primary
human tenocytes might be responsive to the profibrotic
effects of these two cytokines and thus might be used
locally to promote tendon healing in patients with tendi-
nopathies or for tendon tissue-engineering applications.
To begin addressing this hypothesis, we investigated
whether human tendon tissues and primary tenocytes
express IL-4/IL-13 receptor chains. We also assessed the
effects of recombinant human (rh)IL-4 and rhIL-13 on
cultured human tenocytes.
Materials and methods
Patients and tendon tissue samples
Patients with tendinopathies of the AT or PTT were
enrolled in this study. All procedures were reviewed and
approved by the MedStar Research Institute and the Uni-
versity of Maryland Institutional Review Boards.
Informed consent was obtained from all patients.
Tendon tissues that would otherwise be discarded were
obtained from normal and injured/diseased tendons dur-
ing reconstructive surgery procedures performed for
clinical indications. These tissues included the tendinop-
athic portion of the PTT or AT, and the healthy (non-ten-
dinopathic) portion of the flexor digitorum longus (FDL)
tendon, the flexor hallucis longus (FHL) tendon or the
AT. The diseased sections of the tendon were identified
by the characteristic thickening of the outer diameter, fis-
suring, surface irregularity, fibrillation, and a more gelati-
nous consistency and yellowish discoloration compared
with normal tendons; some of the diseased tendons were
also ruptured or attenuated. The specific numbers of
patients involved in each experiment are indicated in the
Results and the figure legends.
Primary tenocyte explant cultures
Separate primary cell cultures were established from
healthy and diseased portions of tendon tissues obtained
from each patient. Harvested tendon tissues were used
either for mRNA purification or for primary explant cell
cultures. For cell culture, the tissues were rinsed twice in
phosphate-buffered saline containing 1% antibiotic mix-
ture (100 μg/ml penicillin and 100 μg/ml streptomycin),
cut into 1 mm3  pieces under sterile conditions, and
digested with 0.25% trypsin (w/v) in ethylenediaminetet-
raacetic acid (EDTA) for 5 min. The digested tissues were
transferred to 35-mm culture dishes and incubated in 5%
CO2/95% air at 37°C with Dulbecco's modified Eagle's
medium/nutrient mix F-12 (DMEM/F12) medium con-
taining 10% fetal bovine serum and 1% antibiotic mixture
as described above. The culture medium was changed
twice a week. Emerging cells were split by trypsinization,
seeded into 75-cm2 culture flasks at 1 × 105 cells per flask,
and cultured in the same high serum (10%) cell culture
medium, until they were split again after reaching
approximately 1 × 106 cells per flask. Tenocyte identity
was confirmed by assessing the expression of a tenocyte-
specific gene (scleraxis) and genes for collagens α1(I),
α2(I) and α1(III) in real-time PCR assays with specific
primers. Cells were used for experiments at passages 3 to
5.  F or  e x pe ri me n ts,  c e lls w e r e  t rypsi nized,  seeded i n t o
six-well plates at 2.5 × 105 cells/well or 96-well plates at
2.5 × 103 cells/well, and incubated overnight in dialyzed
low serum (0.5%) cell culture medium. All experiments
were then performed in the same low serum medium. All
cell culture reagents were from Invitrogen (Carlsbad, CA,
USA).
Cultured tenocytes were stimulated with rhIL-13 or
rhIL-4, which were purchased from R&D Systems (Min-
neapolis, MN, USA). Changes in cell proliferation rates
were assessed in quadruplicate, using a cell proliferation
assay (CellTiter Aqueous; Promega, Madison, WI, USA)
in accordance with the manufacturer's recommendations,
as previously described [18]. The assays were calibrated
with titrated known amounts of tenocytes.
Changes in gene expression were assessed in real-time
quantitative (q)PCR assays as described below. Western
blotting assays for type I collagen levels in tenocyte cellCourneya et al. Fibrogenesis & Tissue Repair 2010, 3:9
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cultures were performed and assessed by densitometry of
the specific protein bands as previously described [19].
Reverse transcriptase qPCR
To obtain mRNA, the tendon tissue samples were imme-
diately sectioned into pieces < 3 mm3 in size, frozen in liq-
uid nitrogen, and pulverized under liquid nitrogen with
mortar and pestle. The tissue pellet was transferred into a
glass tube homogenizer where it was further homoge-
nized in TRIzol reagent (Invitrogen, Carlsbad, CA, USA).
Total mRNA was purified from the processed tendon tis-
sues or from cultured tenocytes using TRIzol, and reverse
transcription performed (SuperScript II Reverse Tran-
scriptase; Invitrogen) in accordance with the manufac-
turer's recommendations. Purification of mRNA from
cultured primary cells was also performed using TRIzol
as recommended. The resulting cDNA samples were used
for real-time qPCR using the following three approaches,
in all of which the 2-ΔΔCt method was used to assess the
amplitude of changes in gene expression induced by IL-
13 and IL-4.
The initial pilot experiments were performed on cDNA
samples from total human tendon tissues in TaqMan
assays with specific primers and probes that were
designed based on GenBank sequences for human IL-
4Rα or IL-13Rα2 using Primer Express V.2.0 software
(Applied BioSystems, Foster City, CA, USA) and synthe-
sized by Integrated DNA Technologies (Coralville, IA,
USA). Primers and TaqMan probe for glyceraldehyde-3-
phosphate dehydrogenase (GADPH) (Applied BioSys-
tems) were used as positive controls. PCR assays were
performed in a thermal cycler (ABI PRISM 7000; Applied
BioSystems), with all samples tested in triplicate for each
target.
Experiments on cultured tenocytes measured expres-
sion levels of scleraxis, IL-13Rα1, IL-13Rα2, IL-4Rα, γc,
and the collagen chains COL1A1, COL1A2 and COL3A1.
As a reference sequence, 18S rRNA was used. All pre-val-
idated primers and chemistry for SYBR Green detection
were from SABiosciences (Frederick, MD, USA). The lack
of primer dimers and the specificity of amplification were
further confirmed by agarose gel electrophoresis of PCR
products, which all gave a single band of expected size,
and by automated sequencing of PCR products. Thermal
cycling was performed using a real-time PCR system
(StepOnePlus; Applied BioSystems), and all samples were
tested in triplicate for each target.
Finally, quantitative profiling of genes related to cell
cycle regulation or, separately, connective tissue, was per-
formed using the RT2 qPCR System (SABiosciences) and
the StepOnePlus system. This approach allowed simulta-
neous real-time qPCR analyses of the mRNA levels of 84
relevant genes, normalized to five different reference tar-
gets (β2-microglobulin, hypoxanthine phosphoribosyl-
transferase 1, ribosomal protein L13a, GAPDH and β-
actin). Combined tenocytes derived from the AT of two
separate donors were stimulated with 150 ng/ml rhIL-13
or rhIL-4, each on two separate occasions, for 6 h or 24 h
as indicated, and RT-qPCR analyses performed. To be
selected, genes had to have a cytokine-stimulated
increase or decrease in gene expression that was consis-
tently equal to or greater than twofold in both IL-13- and
IL-4-stimulated cultures compared with non-stimulated
controls in each independent stimulation. In addition, the
absolute level of expression for each gene was required to
be sufficient, as judged by amplification occurring earlier
than an arbitrarily established threshold of 32 cycles of
PCR amplification.
Results
Primary tenocytes express IL-13R and IL-4R chains
Initial pilot RT-qPCR experiments assessed whether
mRNAs for IL-4Rα and IL-13Rα2 might be expressed in
whole tendon tissues from nine independent donors
(Table 1). These assays tested PTT and FDL tissues from
six donors, FHL tissue from one donor and AT tissues
from three donors (T able 1). In most cases, expression
levels of IL-4Rα and IL-13Rα2 mRNAs were similar to
those of the ubiquitous GAPDH mRNA; an irrelevant tar-
get IL-6 amplified much later in the cycle, suggesting sub-
stantially lower levels of IL-6 mRNA in whole tendon
tissues (Table 1). We considered that the surgically
obtained whole tendon tissues might be contaminated
with blood or adjacent non-tendon tissues, therefore sub-
sequent experiments were performed on cultured teno-
cytes. RT-qPCR experiments revealed that cultured
primary tenocytes but not pulmonary fibroblasts or T
cells expressed scleraxis mRNA (Figure 1a), thus confirm-
ing the phenotypic identity of these cells as tenocytes.
Tenocytes and pulmonary fibroblasts but not T cells
expressed mRNAs for collagen chains (Figure 1a). Note
that all tested mesenchymal cells expressed IL-4Rα, IL-
13Rα1 and IL-13Rα2 chains, but only T cells expressed
the γc in combination with IL-4Rα chain. Quantitative
analyses (Figure 1b) revealed that tenocytes express
higher levels of IL-13R chains compared with IL-4Rα.
These observations suggested that tenocytes might be
responsive to stimulation with IL-13 or IL-4, as these two
cytokines are known to share receptor chains. Therefore,
tenocytes were stimulated with rhIL-13 or rhIL-4 in the
subsequent experiments.
Primary tenocytes proliferate in response to stimulation 
with IL-13 or IL-4
Stimulation with rhIL-13 or rhIL-4 leads to dose-depen-
dent increases in tenocyte proliferation rates (Figure 2).
One-way ANOVA analyses revealed that the increases
were significant at cytokine concentrations of 10 to 300Courneya et al. Fibrogenesis & Tissue Repair 2010, 3:9
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ng/ml. Note that in both cases, the increase in prolifera-
tion rate was between 1.5- and 2-fold at a concentration
of 150 ng/ml. The effect of IL-13 remained approximately
the same or was further increased at 300 ng/ml, whereas
the maximum effect of IL-4 was observed at 50 ng/ml,
with a gradual decline at 150 ng/ml and 300 ng/ml. In
addition to the two AT tenocytes cultures and one PTT
culture shown in Figure 2, we tested the effect of a single
concentration of 150 ng/ml IL-13 or IL-4 on four other
PTT and four FDL tenocyte cultures. There were no dif-
ferences in-fold increases of proliferation rates induced
by IL-13 or IL-4, or between PTT or FDL tenocyte cul-
tures (P > 0.05, two-tailed Student's t-test). The average
increase in proliferation rates at this single concentration
of either IL-13 or IL-4 was 1.75 ± 0.27-fold compared
with non-stimulated control cultures.
To identify the molecular pathway through which IL-13
and IL-4 may regulate tenocyte proliferation, we used RT-
qPCR to assess changes in the expression level of 84 mol-
ecules known to be involved in the cell-cycle regulation.
We combined equal amounts of tenocytes derived from
the ATs of two volunteers, stimulated them with rhIL-13
or rhIL-4 for 6 and 24 hrs on two independent occasions,
and performed RT-qPCR and analyzed gene expression
as described in Methods. The expression levels of only
four genes were changed at 6 h, but those of 16 genes
were changed at 24 h, with only two genes (CDK6 and
CDKN2B) consistently changed at 6 h and 24 h (Table 2).
It is likely that these pathways mediate the effects of IL-13
and IL-4 on tenocyte proliferation.
The effect of IL-13 and IL-4 on collagen production by 
cultures tenocytes is inconsistent
We then assessed whether IL-13 or IL-4 can induce pro-
duction of collagen in cultured primary AT, PTT or FDL
tenocytes. AT tenocytes were derived from separate
healthy or diseased tendon sections taken from the same
donor. PTT and FDL tenocytes were from a separate
patient, and were tested on two independent occasions.
Steady-state levels of COL1A1, COL1A2 and COL3A1
mRNAs were assessed at 0, 1.5, 3, 6 and 24 hrs of stimula-
tion with 50, 150 or 300 ng/ml rhIL-13. The-fold differ-
ence between stimulated and non-stimulated tenocytes
cultures varied from 0.8 to 1.3, and did not reach signifi-
cance in any instance (P > 0.05, one-way ANOVA).
Table 1: Real-time PCR values for indicated target genes in mRNA purified from tendon tissue samples.
Patient Tendon tissue State Ct , mean ± SDa
GAPDH IL-4Rα IL-13Rα2I L - 6
1 FDL Healthy 23.3 ± 0.3 25.8 ± 0.6 26.1 ± 0.1 32.1 ± 0.1
PTT Diseased 23.8 ± 0.2 24.7 ± 0.1 24.4 ± 0.4 32.2 ± 0.1
2 FDL Healthy 27.5 ± 0.7 32.4 ± 0.5 33.2 ± 0.5 37.0 ± 0.6
PTT Diseased 24.7 ± 0.5 26.7 ± 0.1 25.6 ± 0.6 37.7 ± 0.9
3 FDL Healthy 25.0 ± 0.4 30.0 ± 0.8 31.3 ± 0.7 34.1 ± 0.9
PTT Diseased 26.1 ± 0.5 29.6 ± 0.6 21.8 ± 0.8 35.0 ± 0.8
4 FHL Healthy 26.5 ± 0.3 27.1 ± 0.2 ND 38.8 ± 0.8
AT Diseased 27.3 ± 0.1 30.0 ± 0.3 ND U
5 FDL Healthy 27.9 ± 0.6 30.2 ± 0.5 31.1 ± 0.5 36.6 ± 0.7
PTT Diseased 28.4 ± 0.7 30.0 ± 0.6 31.7 ± 0.7 35.8 ± 0.6
6 FDL Healthy 29.2 ± 0.9 32.4 ± 0.8 31.3 ± 0.7 U
PTT Diseased 30.1 ± 0.9 32.2 ± 0.8 32.1 ± 0.9 U
7 FDL Healthy 29.1 ± 0.7 ND 28.8 ± 0.6 36.8 ± 0.9
PTT Diseased 28.6 ± 0.6 ND 26.3 ± 0.5 37.0 ± 0.9
8 AT Healthy 25.5 ± 0.2 27.4 ± 0.4 27.5 ± 0.3 35.4 ± 0.8
Diseased 20.2 ± 0.1 22.7 ± 0.3 24.5 ± 0.3 34.4 ± 0.7
9 AT Healthy 26.5 ± 0.4 29.3 ± 0.5 U 36.2 ± 0.7
Diseased 26.5 ± 0.3 25.9 ± 0.3 25.9 ± 0.6 31.0 ± 0.6
aEach cDNA sample was tested in triplicate.
AT = Achilles tendon; FDL = flexor digitorum longus; FHL = flexor hallucis longus; ND = no data (not tested); PTT = posterior tibial tendon; U 
= undetermined (no amplification up to PCR cycle 40).Courneya et al. Fibrogenesis & Tissue Repair 2010, 3:9
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Western blotting assays assessed production of type I
collagen protein in separate primary AT tenocyte cul-
tures derived from healthy and diseased sections of the
tendons, each from three different patients, and in a pri-
mary FHL tenocyte culture from a fourth patient. Each
experiment was repeated on two independent occasions.
The changes in the density of collagen bands varied from
0.9 to 1.2-fold in IL-13-stimulated samples compared
with non-stimulated controls (P  > 0.05, one-way
ANOVA). By contrast, stimulation of tenocytes with 1
ng/ml of recombinant human transforming growth fac-
tor-β (used as a positive control) induced a 3.3 ± 0.2-fold
increase in the density of the collagen band (P < 0.05,
two-tailed Student's t-test, data not shown).
Based on these observations, we concluded that IL-13
has minimal, if any, effect on collagen production in cul-
tured tenocytes. To further assess whether IL-13 or IL-4
might have any effect on other extracellular matrix
(ECM)-related genes, RT-qPCR (RT2 real-time PCR Sys-
tem; SABiosciences) was used to measure gene expres-
sion for 84 genes related to the ECM, with results
normalized to those from five housekeeping genes. In
these experiments, AT tenocytes from two volunteers
were pooled and stimulated with 150 ng/ml of IL-4 or IL-
13 for 6 h, each on two independent occasions, and the
gene expression was tested by RT-qPCR. Again, there
were no significant changes in the expression of collagen
type I or type III chain genes, nor were there consistent
changes in the expression of the majority of tested genes
within two-fold differences. Only five genes (Table 3) met
the criteria described in the Methods section (consistent
significant change induced by both IL-13 and IL-4).
Discussion
We found that primary human tenocytes derived from
healthy tendon tissues and tendon segments involved in
tendinopathy express the IL-13R and IL-4R chains except
for γc (Figure 1). They respond to stimulation with rhIL-
13 or rhIL-4 by increasing proliferation (Figure 2) but not
collagen production, and by changing expression of sev-
eral genes, including those for cell cycle-related factors
(Table 2) and ECM- and cell adhesion-related factors
Figure 1 Reverse transcriptase quantitative (q)PCR analyses of interleukin (IL)-4 receptor (R)/IL-13R mRNA expression . (a) Ethidium bromide 
gels of PCR products after 35 cycles of qPCR with cDNAs from cultured indicated cells with indicated primers. Tenocytes (Tenoc) expressed scleraxis 
mRNA, confirming the phenotypic identity of these cells. Tenocytes and pulmonary fibroblasts but not T cells expressed mRNA for collagen chains. 
All tested cell types expressed IL-4Rα mRNA, and all cell types except T cells expressed IL-13Rα1 and IL-13Rα1 mRNAs. Only T cells expressed common 
gamma chain (γc). (b) Quantitative analyses reveal relative expression of receptor chains in cultured tenocytes from indicated tendons of five separate 
donors (SYBR Green-based quantification, normalized to 18S rRNA). The prime marks indicate separate cultures developed at a different time from the 
same tissue source and analyzed at a different passage. A549 = transformed pulmonary epithelial cell line; NHLF = normal human lung fibroblasts, 
PBMC = peripheral blood mononuclear cells from a healthy volunteer.
Figure 2 Effects of IL-13 and IL-4 on proliferation of primary ten-
ocytes . Stimulation with (a) IL-13 or (b) IL-4 accelerated proliferation 
of primary tenocytes in a dose-dependent fashion (CellTiter Aqueous 
assays, day 7). Data show fold increase in proliferation rate ± SD, in ten-
ocytes derived from indicated tendon types.Courneya et al. Fibrogenesis & Tissue Repair 2010, 3:9
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(Table 3). Thus, IL-4 and IL-13 might have therapeutic
potential as tendon-healing agents used locally; the sys-
temic use of these immunomodulatory cytokines is not
advisable because of the danger of side effects. These
cytokines might also be useful in future tendon tissue-
engineering applications to facilitate tenocyte growth on
artificial scaffolds for subsequent use in reconstructive
tendon surgery.
Stimulation with IL-4 or IL-13 induced changes in
expression of several cell cycle-related genes, particularly
CDK6 and CDKN2B, which were consistently changed at
6 h and 24 h of stimulation (Table 2). Further mechanistic
studies will address the role of each of these factors, with
the ultimate goal of developing novel approaches to fine-
tune tenocyte proliferation. Neither IL-4 or IL-13 had any
effect on collagen mRNA or protein levels or on the
expression of the majority of 84 tested connective tissue-
and cell adhesion-related genes, with a few exceptions
(Table 3). Therefore, these two cytokines might facilitate
tendon repair through their tenoproliferative effects.
Other researchers have already addressed an adjacent
but different hypothesis, by studying the role of germline
deficiency of IL-4 in otherwise healthy mice [20] and in a
mouse model of tendon healing [21]. The results [20,21]
were inconclusive, probably due to numerous acknowl-
edged limitations of their study design, and there were
substantial differences between the study designs of those
previous reports and our current study. Those studies
used a mouse model, whereas we investigated primary
human tendon tissues and tenocytes, thus our results are
more likely to be relevant to human health. Their experi-
ments addressed the importance of natural systemic lev-
els of IL-4 in mice on tendon development, homeostasis
and healing; such natural levels are notoriously low in the
absence of allergy or other Th2 activation. By contrast,
our investigation focused on the therapeutic potential of
high doses of locally administered IL-4 or IL-13. More-
over, the previous studies did not address a potential role
of IL-13, which shares numerous functions with IL-4,
including effects on proliferation and gene expression in
tenocytes (Figure 2, Table 1, Table 2). Because the mice in
the previous reports [20,21] were deficient in IL-4- but
not IL-13, it is logical to expect that IL-13 would signifi-
cantly compensate for the lack of IL-4 in those animal
models. Therefore, our study provides novel findings of
potential applied significance.
In our study, the expression of the IL-4R and IL-13R
chains and the effects of IL-4 and IL-13 were consistent in
tenocytes derived from various donors, various tendon
Table 2: Average fold differences in steady-state mRNA 
levels compared with non-stimulated tenocytes, at 6 h and 
24 h of activation, for cell cycle-related genes.
mRNA 6 h 24 h
IL-4 IL-13 IL-4 IL-13
CDK6 2.22 2.26 3.08 2.62
CDKN2B 0.31 0.32 0.22 0.28
CDKN1A 2.21 2.25 -- --
Nibrin 2.97 3.04 -- --
Cyclin B1 -- -- 0.35 0.33
Cyclin B2 -- -- 0.23 0.21
Cyclin E1 -- -- 3.95 3.97
CDK1 -- -- 0.17 0.14
CDK5 -- -- 6.35 2.1
CDKN3 -- -- 0.16 0.19
Cdc20 -- -- 0.24 0.27
Cdc21 -- -- 2.6 2
Cdc46 -- -- 2.78 1.91
GADD45A -- -- 0.37 0.46
HUS1a -- -- 2.72 1.9
Ki-67b -- -- 0.15 0.2
Dp-1c -- -- 2.05 3.64
p53d -- -- 2.63 3.17
For clarity, the standard deviations are not shown, but the 
variability within each group did not exceed 0.25 cycles of PCR 
amplification.
-- = difference was > 0.5 but < 2.0; Cdc = cell division cycle; CDK = 
cyclin-dependent kinase; CDKN = cyclin-dependent kinase 
inhibitor; GADD45A = growth arrest and DNA-damage-inducible 
alpha.
aCheckpoint homolog.
bProliferation-related antigen.
cTranscription factor.
dTumor suppressor protein.
Table 3: Average fold differences in steady-state mRMA 
levels compared with non-stimulated tenocytes, at 6 h of 
activation, for extracellular matrix- and cell adhesion-
related genes.
mRNA IL-4 IL-13
VCAM1 15.88 27.38
Thrombospondin 1 3.92 2.81
Tenascin C 2.66 2.94
ADAMTS 0.21 0.29
Integrin β5 0.22 0.30
For clarity, the standard deviations are not shown, but the 
variability within each group did not exceed 0.25 cycles of PCR 
amplification.
-- = difference was > 0.5 but < 2.0; ADAMTS = A disintegrin-like 
and metalloproteinase with thrombospondin type 1 motif; VCAM 
= vascular cell adhesion molecule.Courneya et al. Fibrogenesis & Tissue Repair 2010, 3:9
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types, and from both healthy and diseased tendon tissues.
All the PTT tissues in this study were from diseased seg-
ments of the tendon and all FDL tissues were from
healthy segments, as autologous FDL was used for surgi-
cal PTT reconstruction in the same patients. AT tissues
were also tested from healthy and diseased segments of
the tendon. Therefore, local use of rhIL-4 and/or rhIL-13
might be broadly applicable for therapeutic facilitation of
tendon healing.
One possible weakness of our study is that the increase
in proliferation rates of tenocytes did not exceed two-
fold, which is relatively modest compared with the effects
of IL-4 on the proliferation rates of immune cells, such as
lymphocytes. However, it is important to keep in mind
that lymphocytes proliferate rapidly upon stimulation but
also undergo rapid apoptosis upon completion of the
immune response. By contrast, tenocytes are ECM-pro-
ducing connective tissue cells, and large-amplitude
changes in connective tissue would have far-reaching
structural and functional consequences. It is, therefore,
plausible that the amplitude of changes in this study was
consistent with previous observations in fibroblasts from
tissues other than tendons that respond to stimulation
with IL-4 or IL-13 with similar amplitude [16-18]. Thus,
the results of this study are relevant and significant.
The biological purpose for the receptor expression and
responsiveness to IL-4 and IL-13 in primary tenocytes is
not clear. These two cytokines are commonly involved in
allergic and antiparasitic immune responses. However, it
would be difficult to imagine such immune reactions in
the tendon, which is very compact, highly fibrotic tissue,
whose sheer density prevents the degree of swelling and
immune cell extravasation commonly seen in other tis-
sues. Therefore, it is unlikely that tendon tissue would
contain numerous IL-4 or IL-13-producing cells (such as
T cells) or participate in classic immune reactions [13].
We did not observe any IL-4 or IL-13 mRNA production
in tendon tissues or cultured primary tenocytes by RT-
qPCR (data not shown). We also performed experiments
in which primary AT and PTT tenocytes at passage 3
were stimulated with 100 ng/ml of either rhTNF-α, rhIL-
1β or rhIFN-γ for 6 h or 24 h, with levels of IL-4 and IL-13
mRNAs measured by RT-qPCR in these samples. No
PCR product was detected for IL-4 or IL-13 mRNA
before or after stimulation with rhTNF-α, rhIL-1β or
rhIFN-γ at these times. In the same experiments, the IL-4
and IL-13 mRNA targets were readily detectable in the
same amount of total RNA (as judged by similar RT-
qPCR amplification of an 18s rRNA reference target)
from purified primary T cells (positive control, data not
shown). However, other authors have recently reported
that another interleukin, IL-10, is also biologically active
in tenocytes [22,23], further suggesting that primary ten-
ocytes do proliferate and change gene expression in
response to immunomodulatory cytokines, thus this fea-
ture might be useful for biomedical applications.
Conclusions
Primary human tenocytes derived from healthy and dis-
eased tendon tissue express IL4Rα, IL-13Rα1 and IL-
13Rα2 chains but not the γc chain. Both rhIL- 4 and rhIL-
13 stimulate tenocyte proliferation and regulate expres-
sion of several genes, including genes whose protein
products control the cell cycle; however, neither cytokine
consistently regulates production of collagen in primary
tenocytes. These observations suggest that local adminis-
tration of IL-4 and/or IL-13 to the healing tendon might
be beneficial in accelerating recovery in patients with ten-
dinopathies, without affecting systemic regulation of
i n f l a m m a t i o n  o r  i m m u n i t y  b y  t h e s e  c y t o k i n e s .  T h e s e
cytokines might be also used in tendon tissue-engineer-
ing applications, to facilitate the growth or primary,
including autologous, tenocytes on scaffolds, to be used
as implants in reconstructive tendon surgery.
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